<div id="readability-page-1"><div><h2>Why Nektar Therapeutics (NKTR) is on investor radar</h2> <p>Nektar Therapeutics (NKTR) has drawn fresh attention after recent trading saw the stock move against a backdrop of mixed performance, with a modest gain over the past month but a stronger recovery across the past 3 months.</p> <p>See our latest analysis for Nektar Therapeutics.</p> <p>At a latest share price of $78.43, Nektar’s recent pullback over the past week contrasts with an 18.2% 3 month share price return and a very large 1 year total shareholder return. Together, these figures suggest sentiment has shifted meaningfully compared with its longer term track record.</p> <p>If you are looking beyond a single biotech stock, this could be a useful moment to size up other healthcare focused opportunities using our screener of 33 healthcare AI stocks</p> <p>With Nektar’s share price already up strongly over the past year but still trading at a very large discount to the consensus price target, you have to ask: is there real upside left here, or is the market already pricing in future growth?</p> <h2>Most Popular Narrative: 46% Undervalued</h2> <p>At a last close of $78.43 against a fair value estimate of $144.25, the most followed Nektar narrative frames the recent rally as only part of the story.</p> <blockquote> <p><em>Robust cash position after the recent equity raise extends runway into 2027, providing operational stability to advance late-stage assets and initiate Phase III trials without near-term dilution or financing risk. This supports earnings predictability and reduces financial leverage concerns.</em></p> </blockquote> <p>Read the complete narrative.</p> <p>Curious what has to happen between now and 2029 for that fair value to make sense? Revenue paths, margin shifts and a very demanding earnings multiple all sit at the core of this narrative.</p> <p><strong>Result: Fair Value of $144.25 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this hinges on rezpegaldesleukin delivering in larger Phase 3 trials and on Nektar managing ongoing losses without relying heavily on fresh equity funding.</p> <p>Find out about the key risks to this Nektar Therapeutics narrative.</p> <h2>Another Way to Look at Nektar’s Valuation</h2> <p>The analyst narrative points to a fair value of $144.25, yet Nektar trades on a P/S of 47.6x versus 4.8x for the US pharmaceuticals sector and a fair ratio of 19.4x. That big gap raises a simple question: is the upside story already embedded in today’s rich multiple?</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/865b8876-5e88-471e-afbe-a53c94767469/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/865b8876-5e88-471e-afbe-a53c94767469/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTEz"/><figcaption>NasdaqCM:NKTR P/S Ratio as at May 2026</figcaption></figure><h2>Next Steps</h2> <p>Mixed signals so far, with strong optimism but clear concerns in the background, so check the data yourself, weigh both sides, and see the 1 key reward and 3 important warning signs</p> <h2>Looking for more investment ideas?</h2> <p>If Nektar has caught your attention, do not stop there. Use this momentum to broaden your watchlist and pressure test your next moves across other opportunities.</p> <ul> <li>Spot potential value by scanning a focused list of quality companies trading below their estimated worth with the help of 44 high quality undervalued stocks.</li> <li>Prioritise resilience by reviewing 69 resilient stocks with low risk scores that score well on stability, financial strength, and lower overall risk profiles.</li> <li>Hunt for tomorrow’s potential standouts before they hit the headlines with a screener containing 22 high quality undiscovered gems that filters for strong fundamentals.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Nektar Therapeutics might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

NKTR

LABU

<p>Nektar Therapeutics (NKTR) has gained attention due to a recent share price recovery, currently at $78.43, despite a mixed performance. The stock has seen an 18.2% return over three months and a significant one-year total shareholder return. Analysts estimate a fair value of $144.25, indicating it is undervalued. The company has a robust cash position, allowing it to advance late-stage assets without immediate financing risks. However, concerns remain about its high P/S ratio of 47.6x compared to the sector average of 4.8x, raising questions about future growth potential.</p>

Simplywall

Nektar Therap

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VG Health

Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery